Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

Ionis Pharmaceuticals, Inc. (IONS) announced that the FDA has granted a Fast Track designation to eplontersen for the treatment of adult patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).ATTR-CM is a progressive and fatal disease that is caused by the accumulation of misfolded TTR protein in the cardiac muscle.Ionis is developing eplontersen in partnership with British drugmaker AstraZeneca (AZN) .The phase III CARDIO-TTRansform study is currently evaluating eplontersen for treating ATTR ...